NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
Clinical Trials
6 trialsNCT05469919 2024-08-02
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT02630199 2022-06-15
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
Phase 1 Completed
NCT03022409 2021-08-10
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
Phase 1 Completed